

SUPPLEMENTARY TABLE

Supplementary table S1. Characteristics of the pSS study population.

Patient characteristics	N=262
Age (years)	56 ± 15
Female	244 (93)
Time since diagnosis of pSS (years)	6 (2-11)
Duration of symptoms (years)	13 (8-20)*
Smoking	
Current smoker	24 (10)
Previous smoker	57 (23)
Non-smoker	170 (68)
ESSPRI	6 (5-8)*
ESSDAI	4 (1-7)
Salivary gland biopsy, focus score ≥1	203 (89)
Laboratory parameters	
Anti-SSA positive	242 (93)
Anti-SSB positive	149 (58)
ANA positive	245 (94)
IgG (g/L)	15.9 (11.6-20.2)
RF (kU/L)	30 (13-65)*
Complement C3 (g/L)	1.14 ± 0.24
Complement C4 (g/L)	0.20 ± 0.075
Cryoglobulinemia	44 (24)*
Paraproteinemia	13 (6)*
Current medication use	
Biologic DMARDs	6 (2)
Synthetic DMARDs	65 (25)
Corticosteroids	26 (10)
NSAIDs	86 (33)
Inhalation corticosteroids	29 (11)
Beta-2-sympathomimetics	14 (5)

Parameters are expressed as “mean ± standard deviation (SD)”, “median (interquartile range; IQR)” or “number (percentage)”. Abbreviations: ANA, antinuclear antibodies; DMARDs, disease-modifying antirheumatic drugs; ESSDAI, EULAR Sjögren’s Syndrome Disease Activity Index; ESSPRI, EULAR Sjögren’s Syndrome Patient Reported Index; IgG, immunoglobulin G; NSAIDs, Non Steroid Anti Inflammatory Drugs; RF, rheumatoid factor.

*Data were missing for 20-37% of the patients.

Supplementary table S2. Characteristics of pSS patients with and without ILD.

Patient characteristics	ILD (n=15)	No ILD (n=247)	P-value
Age (years)	64 (59-77)	57 (46-66)	0.039
Female	14 (93)	230 (93)	1.000
Time since diagnose (years)	9 (3-17)	6 (2-11)	0.252
Time since start symptoms (years)	20 (9-25)	13 (8-19)	0.230
Smoking			0.280
Current Smoker	0 (0)	24 (10)	
Previous smoker	5 (36)	52 (22)	
Non-smoker	9 (64)	161 (68)	
ESSPRI	6 (5-8)	6 (5-8)	0.723
ESSDAI	12 (4-20)	3 (1-6)	0.000
Salivary gland biopsy, focus score ≥ 1	13 (100)	190 (89)	0.370
Laboratory parameters			
Anti-SSA positive	15 (100)	227 (93)	0.608
Anti-SSB positive	9 (64)	140 (58)	0.623
ANA	13 (87)	232 (95)	0.190
IgG titer (g/L)	15.9 (8.7-23.3)	15.9 (11.9-20.1)	0.847
RF (kU/L)	11 (0-30)	33 (14-68)	0.011
Complement C3 (g/L)	1.08 (0.95-1.31)	1.14 (0.99-1.30)	0.504
Complement C4 (g/L)	0.19 (0.15-0.26)	0.20 (0.16-0.24)	0.945
Cryoglobulinemia	4 (29)	40 (23)	0.744
Paraproteinemia	1 (8)	12 (6)	0.575
Current medication use			
Biologic DMARDs	1 (7)	5 (2)	0.301
Synthetic DMARDs	6 (40)	59 (24)	0.161
Corticosteroids	5 (33)	20 (8)	0.008
NSAIDs	6 (40)	80 (32)	0.542
Inhalation corticosteroids	2 (13)	27 (11)	0.675
Beta-2-sympathomimetics	1 (7)	13 (5)	0.573

Parameters are expressed as “median (interquartile range; IQR)” or “number (percentage)”. Abbreviations: ANA, antinuclear antibodies; DMARDs, disease-modifying antirheumatic drugs; ESSDAI, EULAR Sjögren’s Syndrome Disease Activity Index; ESSPRI, EULAR Sjögren’s Syndrome Patient Reported Index; IgG, immunoglobulin G; ILD, interstitial lung disease; NSAIDs, Non Steroid Anti Inflammatory Drugs; RF, rheumatoid factor.